Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Friborg

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Virology|July 30, 2013
Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell linesJacques Friborg, Baiqing Lin, Chaoqun Chen, et al.
The Journal of Infectious Diseases|May 4, 2004
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimensRichard Colonno, Ronald Rose, Colin McLaren, et al.
Infectious Diseases and Therapy|December 18, 2014
In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus AsunaprevirJacques Friborg, Nannan Zhou, Zhou Han, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 18, 2014
Endogenous IFNλ in viral hepatitis patientsRik A de Groen, Fiona Mcphee, Jacques Friborg, et al.
Plos One|April 1, 2015
Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytesJacques Friborg, Petra Ross-Macdonald, Jian Cao, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2005
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitorsJoseph Yanchunas, David R Langley, Li Tao, et al.
Antimicrobial Agents and Chemotherapy|January 1, 2013
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replicationJacques Friborg, Steven Levine, Chaoqun Chen, et al.
Antiviral Therapy|August 6, 2011
Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolatesAmy K Sheaffer, Min S Lee, Dennis Hernandez, et al.
European Journal of Immunology|October 16, 2014
IFN-λ-mediated IL-12 production in macrophages induces IFN-γ production in human NK cellsRik A de Groen, Arjan Boltjes, Jun Hou, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2012
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevirFiona McPhee, Jacques Friborg, Steven Levine, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Virology|July 30, 2013
Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell linesJacques Friborg, Baiqing Lin, Chaoqun Chen, et al.
The Journal of Infectious Diseases|May 4, 2004
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimensRichard Colonno, Ronald Rose, Colin McLaren, et al.
Infectious Diseases and Therapy|December 18, 2014
In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus AsunaprevirJacques Friborg, Nannan Zhou, Zhou Han, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 18, 2014
Endogenous IFNλ in viral hepatitis patientsRik A de Groen, Fiona Mcphee, Jacques Friborg, et al.
Plos One|April 1, 2015
Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytesJacques Friborg, Petra Ross-Macdonald, Jian Cao, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2005
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitorsJoseph Yanchunas, David R Langley, Li Tao, et al.
Antimicrobial Agents and Chemotherapy|January 1, 2013
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replicationJacques Friborg, Steven Levine, Chaoqun Chen, et al.
Antiviral Therapy|August 6, 2011
Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolatesAmy K Sheaffer, Min S Lee, Dennis Hernandez, et al.
European Journal of Immunology|October 16, 2014
IFN-λ-mediated IL-12 production in macrophages induces IFN-γ production in human NK cellsRik A de Groen, Arjan Boltjes, Jun Hou, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2012
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevirFiona McPhee, Jacques Friborg, Steven Levine, et al.
Pageof 3